Get the Stockscreener App
0.7349
26.34%
0.1532
After Hours:
.73
-0.0049
-0.67%
Humacyte Inc stock is traded at $0.7349, with a volume of 21.39M.
It is up +26.34% in the last 24 hours and up +10.56% over the past month.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$0.5817
Open:
$0.6
24h Volume:
21.39M
Relative Volume:
1.99
Market Cap:
$204.15M
Revenue:
$2.02M
Net Income/Loss:
$-97.59M
P/E Ratio:
-1.2788
EPS:
-0.5747
Net Cash Flow:
$-102.38M
1W Performance:
+10.51%
1M Performance:
+10.56%
6M Performance:
-36.10%
1Y Performance:
-53.92%
1-Day Range:
$0.5964
$0.75
1-Week Range:
$0.5261
$0.75
52-Week Range:
$0.5261
$2.55
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
0.7349 | 161.60M | 2.02M | -97.59M | -102.38M | -0.5747 |
VRTX
Vertex Pharmaceuticals Inc
|
552.06 | 133.88B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
840.84 | 83.42B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
174.38 | 25.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
1,032.86 | 62.12B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
214.66 | 46.30B | 742.00K | -1.37B | -1.07B | -7.0731 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Initiated | Barclays | Overweight |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Humacyte (HUMA) Q2 2026 Earnings Call Transcript - AOL.com
Humacyte publishes Phase 3 trial results in Lancet journal By Investing.com - Investing.com Canada
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results - The Manila Times
Humacyte Announces Lancet Digital Health Publication Of V007 Phase 3 Hemodialysis Access Trial Results - TradingView
A bioengineered vessel beat fistulas for women and men with obesity and diabetes on dialysis - Stock Titan
Fresenius Medical Care stock trades close to recent NYSE levels as Humacyte stake sale draws attenti - Ad-hoc-news.de
Major Humacyte (HUMA) holder sells shares under 10b5‑1 plan - Stock Titan
Humacyte Announces First Symvess Implants in Arizona by Phoenix Vascular Surgeon Jeromy Brink - Quiver Quantitative
A bioengineered blood vessel is ready off the shelf for urgent surgery - Stock Titan
HC Wainwright Predicts Humacyte's Q3 Earnings (NASDAQ:HUMA) - MarketBeat
Humacyte (NASDAQ:HUMA) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Humacyte (HUMA) Faces A Fresh Test As Its $4 Fair Value Narrative Holds - Yahoo Finance
Price to earnings forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Price to book forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Enterprise value to EBITDA forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Benchmark Lowers Humacyte (NASDAQ:HUMA) Price Target to $1.00 - MarketBeat
Humacyte (HUMA) Stock Looks Stretched On Book Value Yet Reasonable After A 93% Fall - Yahoo Finance
Humacyte earnings missed by $0.07, revenue fell short of estimates - Investing.com Nigeria
Humacyte (HUMA) Reports Stronger Phase 3 Dialysis Results In Women - Yahoo Finance
Humacyte Q2 Revenue Rises to $0.4 Million as Net Loss Narrows - Moomoo
Humacyte Inc (HUMA) (Q2 2026) Earnings Call Highlights: Strong Trial Results and Strategic ... - Yahoo Finance Australia
Humacyte, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Humacyte, Inc. Q2 2026: Revenue $406K, EPS $(0.16) — 10-Q Summary - TradingView
Humacyte (NASDAQ: HUMA) logs $54.4M loss and flags going concern risk - Stock Titan
HUMA Q2 FY2026 earnings call - finance.biggo.com
Sutro Biopharma, Humacyte, CoreWeave - TradingView
Humacyte (NASDAQ:HUMA) Releases Quarterly Earnings Results - MarketBeat
Humacyte stock maintained at Buy by BTIG on pipeline progress - Investing.com Canada
Humacyte Q2 Results: Sales Miss Estimate by 64%, Loss Widens - scanx.trade
Earnings call transcript: Humacyte misses Q2 2026 estimates as shares fall premarket - Investing.com Nigeria
Humacyte Inc reports results for the quarter ended June 30Earnings Summary - TradingView
HUMA: Q2 2026 marked clinical breakthroughs, commercial momentum, and robust financial positioning - TradingView
Transcript : Humacyte, Inc., Q2 2026 Earnings Call, Aug 12, 2026 - marketscreener.com
HUMA: Breakthrough clinical results and commercial momentum position for growth and new launches in 2027 - TradingView
Humacyte Q2 Earnings Call Highlights - TradingView
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Humacyte, Inc. (HUMA) Q2 FY2026 earnings call transcript - Yahoo Finance
Form 8K Humacyte Inc For: 12 August By Investing.com - Investing.com Australia
HUMACYTE ($HUMA) Releases Q2 2026 Earnings - Quiver Quantitative
Form 8K Humacyte Inc For: 12 August - Investing.com India
Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Humacyte reports Q2 2026: Product revenue $0.4M, net loss $36.8M, cash $80.3M - TradingView
Humacyte Reports Breakthrough V012 Dialysis Access Results, FDA Accepts CTEV IND, and Second-Quarter 2026 Financial Results - Quiver Quantitative
Humacyte Q2 revenue rises to $0.4 million as net loss narrows - Quiver Quantitative
BRIEF-Humacyte Q2 Operating Expenses USD 27.402 Million - TradingView
Humacyte (NASDAQ:HUMA): What Could Today’s commercial adoption and manufacturing Update Reveal? - Kalkine Media
Humacyte Inc (HUMA) (Q2 2026) Earnings Call Highlights: Strong Trial Results and Strategic ... By GuruFocus - Investing.com Canada
Humacyte Inc (HUMA) Q2 2026 Earnings Report Preview: What To Expect - Yahoo Finance
Humacyte Inc (HUMA) Q2 2026 Earnings Report Preview: What To Exp - GuruFocus
Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc.HUMA - Business Wire
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.42%
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):